| Quantity: | |
|---|---|
Clinically relevant – Mimics human ulcerative colitis: acute inflammation, mucosal ulcers, bloody diarrhea, weight loss.
Well-characterized endpoints – Disease Activity Index (DAI) score, body weight, stool consistency, fecal occult blood, colon length, histopathology.
Reproducible and simple – DSS-induced model is widely used for its simplicity and reproducibility.
Translational value – Ideal for testing anti-inflammatory drugs, biologics (anti-TNF, anti-integrin), JAK inhibitors, and microbiome modulators.
IND-ready data packages – Studies can be conducted in accordance with GLP principles.
Representative data from our DSS Induced NHP IBD model:
DSS Induced IBD Model in Non-human Primate
• Efficacy testing of anti-inflammatory drugs (5-ASA, corticosteroids), biologics (anti-TNF, anti-IL-12/23, anti-integrin), JAK inhibitors, and S1P receptor modulators
• Target validation for inflammatory pathways in IBD
• Biomarker discovery (fecal calprotectin, cytokines, microbiome analysis)
• Mechanism of action (MOA) studies
• IND-enabling toxicology and safety pharmacology studies
Parameter | Specification |
Species | Cynomolgus macaque (Macaca fascicularis) |
Induction method | Oral administration of dextran sulfate sodium (DSS) in drinking water for 5–10 days |
Study duration | 2–4 weeks (induction + treatment phase) |
Key endpoints | Disease Activity Index (DAI) score, body weight, stool consistency, fecal occult blood, colon length, histopathology (crypt damage, inflammatory infiltration), MPO activity, cytokine levels (TNF-α, IL-1β, IL-6) |
Data package | Raw data, analysis reports, histology slides, bioinformatics (optional) |
Q: How is the NHP IBD model induced?
A: By oral administration of dextran sulfate sodium (DSS) in drinking water for 5-10 days, which induces acute colonic epithelial injury and inflammation, mimicking human ulcerative colitis.
Q: What are the key similarities with human ulcerative colitis?
A: The model exhibits weight loss, diarrhea, bloody stools, mucosal inflammation, crypt damage, and neutrophil infiltration, closely resembling human UC pathology.
Q: Can this model be used for IND-enabling studies?
A:Yes. Studies can be conducted in accordance with GLP principles for regulatory submissions (FDA, EMA).
Q: Do you offer customized study protocols (e.g., different DSS concentrations, treatment duration)?
A: Absolutely. Our scientific team tailors DSS dosing regimens, treatment schedules, and endpoint analyses to your specific drug candidate.